CGIX 5.76 Cancer Genetics Inc $CGIX Hit a 52 week low of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 20, 2014 at 11:14 AM

CGIX 5.76 Cancer Genetics Inc $CGIX Hit a 52 week low of 5.56 Closing the day 10:45 at 5.76 -0.19 -3.19% With a day low of 5.56 and a total volume of 41,986.

CGIX Recent Posts: http://investorshangout.com/Cancer-Genetics-Inc-CGIX-88009/

CGIX Cancer Genetics Inc Recent Headline News

Cancer Genetics, Inc. to Present at American Society of Hematology (ASH) Annual Meeting
GlobeNewswire - Mon Nov 17, 6:50AM CST
-- Cancer Genetics will present two posters on diffuse large B-cell lymphoma (DLBCL), the most common form of B-cell cancers.
CGIX: 5.73 (-0.22)

Cancer Genetics, Inc. Recognized in Deloitte's 2014 Technology Fast 500(TM) Awards
GlobeNewswire - Fri Nov 14, 7:06AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the company"

, an emerging leader in DNA-based cancer diagnostics, today announced it ranked 303 on Deloitte's Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. CGI grew 296% percent as measured by revenues during this period.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc to Present at Canaccord Genuity Medical Technology & Diagnostics Conference
GlobeNewswire - Thu Nov 13, 6:55AM CST
Cancer Genetics, Inc., (Nasdaq:CGIX) an emerging leader in DNA-based cancer diagnostics, announced today that the company's CEO, Panna Sharma, will present at the upcoming Canaccord Genuity Medical Technology & Diagnostics Conference. The event, which will be held at the Westin Grand Central in New York on Thursday, November 20, will profile over 80 public and private med-tech and diagnostic companies.
CGIX: 5.73 (-0.22)

Cancer Genetics wins second patent for FHACT test to improve cervical cancer detection for up to 2m women in the US each year
M2 - Wed Nov 12, 7:02AM CST
Cancer diagnostics company Cancer Genetics (NasdaqCM:CGIX) disclosed on Tuesday the receipt of the second US patent (US Patent No. 8,883,414) for its proprietary FISH-based HPV-Associated Cancer Test (FHACT) for cervical cancer detection in patients.
CGIX: 5.73 (-0.22)

RedChip Issues Research Note on Cancer Genetics
GlobeNewswire - Wed Nov 12, 7:00AM CST
RedChip Companies, Inc., today announced it has issued a research note on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc to Present on Company's Targeted Next-Generation Sequencing Panels at AMP
GlobeNewswire - Wed Nov 12, 6:55AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that it will present on its next generation sequencing (NGS) panels for hematological malignancies at the Association for Molecular Pathology's (AMP) 2014 Annual Meeting in Harbor, MD. Principal clinical scientist Charles Ma, Ph.D., will present "Developing NGS-based Clinical Assays for Hematological Neoplasms at CGI" on Wednesday, November 12 at 3 p.m. EST. The talk, which is sponsored by Illumina, will cover the development and clinical utility of the company'sNGS panels for hematologic malignancies, specifically for CLL (chronic lymphocytic leukemia) and Myeloid disorders.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc Receives Second Patent for Genomic Cervical Cancer Test; Strengthens Position of FHACT(R)
GlobeNewswire - Tue Nov 11, 6:55AM CST
-- Company receives second patent (US Patent No. 8,883,414) for FHACT(R)
CGIX: 5.73 (-0.22)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST

UCP: 11.32 (-0.01), JRJC: 6.87 (+0.13), NAVB: 1.21 (-0.01), SANW: 3.68 (+0.16), PLPM: 1.60 (+0.02), RYN: 26.89 (+0.48), INFU: 2.87 (+0.02), LIOX: 5.08 (+0.12), DY: 25.97 (+0.30), MTZ: 24.55 (+0.45), CGIX: 5.73 (-0.22), MUX: 1.51 (+0.05), OREX: 5.67 (-0.01), URRE: 2.14 (unch), ACHN: 13.12 (+0.21), REN: 2.62 (+0.13), MPO: 2.82 (+0.17), AKBA: 14.50 (-0.74), TRX: 1.15 (+0.08), PLNR: 7.27 (+0.04)

Cancer Genetics' (CGIX) CEO Panna Sharma on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 11:28AM CST

CGIX: 5.73 (-0.22)

Cancer Genetics ups revenues 88% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:03AM CST

CGIX: 5.73 (-0.22)

Cancer Genetics Announces Strong Third Quarter With Growth Across All Categories
GlobeNewswire - Mon Nov 10, 7:43AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the third quarter ended September 30, 2014.
CGIX: 5.73 (-0.22)

Cancer Genetics beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:58AM CST

CGIX: 5.73 (-0.22)

Cancer Genetics, Inc. to Report Third Quarter 2014 Financial Results on Monday, November 10
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report third quarter 2014 financial results on Monday, November 10, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the third quarter financial results and to answer questions.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers
GlobeNewswire - Tue Oct 21, 6:59AM CDT
> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT(R))
CGIX: 5.73 (-0.22)

Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML
GlobeNewswire - Mon Oct 13, 6:45AM CDT
> The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
CGIX: 5.73 (-0.22)

Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
PR Newswire - Thu Oct 09, 2:50PM CDT
Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc. to Provide Updates About the Company's Portfolio of Targeted Molecular Diagnostics at Analyst Day on September 25, 2014
GlobeNewswire - Wed Sep 24, 6:45AM CDT
Cancer Genetics Inc. (Nasdaq:CGIX) ("CGI" or "the Company"

, an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina.
CGIX: 5.73 (-0.22)

Cancer Genetics, Inc. and Beth Israel Deaconess Medical Center Enter Into Collaboration to Correlate Genomic Profiles to Patient Outcome in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Tue Sep 23, 6:45AM CDT
-- Study will correlate genetic markers to outcome in ~200 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
CGIX: 5.73 (-0.22)

Cancer Genetics, Inc. to Present at Aegis Healthcare and Technology Conference on Thursday, September 11, 2014
GlobeNewswire - Wed Sep 10, 6:59AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that Panna Sharma will present at the Aegis Healthcare and Technology Conference on Thursday, September 11, 2014 at 8:30 am Pacific Daylight Time (11:30 am EDT).
CGIX: 5.73 (-0.22)

Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE
GlobeNewswire - Tue Sep 02, 7:15AM CDT
- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT(R)) has received the CE Marking.
CGIX: 5.73 (-0.22)

Vyant Bio, Inc. (VYNT) Stock Research Links

VYNT Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Unicoin’s 'RISE IN PINK' Blends Crypto and Charity

The New Face of Charitable Giving: Crypto and Cause Turning the spotlight on how blockchain and altruism can mesh, Unicoin's latest campaign isn’t just your average philanthropic endeavor. With 'RISE IN PINK', they're out to change the game, blending digital assets with a deep human cause—breast cancer awareness and support. Technology Meets Human Cause Imagine...

CardVault by Tom Brady Expands to Pittsburgh

Tom Brady’s CardVault Hits Pittsburgh’s Historic Strip District Pittsburgh just got another feather in its cap with CardVault by Tom Brady marking its 20th store at The Terminal. As if this city needed more sports excitement! Pittsburgh, with its die-hard Steelers, Penguins, and Pirates fans, snags a premium spot for sports collectibles. A Prime Spot for Serious...

Hidden Assets Guide: Essential Tool for Attorneys

Asset Searches: Why They Matter to Lawyers Some days you just have to get into the nitty-gritty of legal legwork, and today feels like one of those days. Asset Search USA has come out swinging with a practical guide that no attorney should ignore, especially if they're dealing with the shadowy world of hidden assets. What are we talking about here? We're talking about...

Qatar's Cultural Ventures Go Big Through 2030

Cultural Partners Lined Up Well Ahead In the swirling world of cultural diplomacy, Qatar's got its eyes set way beyond the skyline with their Years of Culture initiative. Announced recently, they've lined up partners through 2030, locking hands with Italy, the Netherlands, Switzerland, Portugal, and Spain in the coming years. Such moves aren't just for show—they’re...

Roadrunner's Bold Move: New LTL Service and Rate Hike

When you shake up the status quo in logistics, you better be ready for the ride. Roadrunner Freight is doing just that with the launch of its first-ever outbound Canada-to-U.S. LTL service. They're shaking up a market that's been bogged down with inefficiencies for far too long. This isn't just another lane to add to a map; it's a new passage for Canadian goods, paving a...

dMY IV Settlement: Investor Rights and Key Dates

dMY IV Settlement: What You Need to Know Listen up, folks! If you've got a stake in dMY Technology Group, Inc. IV, there's big news brewing. We're talking class action, settlement talks, and a cool $11 million on the line. Let's crack open what this means for you as a holder of dMY IV Class A common stock during December 2021's whirlwind. Who Can Get a Piece of the...

Podcast Giants Converge in Tennessee for POD U Summit

Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...

Medicare Limits and Long-Term Care Planning Tips

Grappling with Medicare's Gaps Most folks hear Medicare and feel a sigh of relief—thinking it's a catch-all net for healthcare in your golden years. But hold on, when it comes to long-term care, Medicare's got more holes than Swiss cheese. Cindy Couyoumjian from Cinergy Financial lays it out pretty clear: Medicare doesn't cover what it calls 'custodial care'—you know,...

Gala Spotlights Veterans' Mental Health Support

Champions for Veterans Honored at Headstrong Gala If you ever wondered who stands in the trenches alongside veterans facing mental health battles, this year's Headstrong Gala offered a crystal-clear answer. Held on October 16 at Pier Sixty in New York City, this shiindig wasn’t just about schmoozing over canapés. It was about celebrating the grit and guts of those...

Blockchain Boom: Media Market to Hit $3.33B by 2035

Blockchain is Not Just for Bitcoin Anymore Who would've thought, right? Blockchain's no longer just the playground for cryptocurrency enthusiasts. Today, it's making waves in the media and entertainment sector. Latest numbers from Credence Research have this market set to explode from $748 million in 2025 to a jaw-dropping $3.33 billion by 2035. Yeah, folks, that's a...